menu
    • menu
    [{"orgOrder":0,"company":"Nanjing Chia-tai Tianqing Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Nanjing Chia-tai Tianqing Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Beijing CTSmed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Overseas Pharma \/ Beijing CTSmed","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Beijing CTSmed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Sao Paulo \/ Takeda Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals for Ramelteon

    Menu

    Ramelteon

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Overseas Pharma

                            India arrow
                            BioJapan
                            Not Confirmed

                            Overseas Pharma

                            India arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Beijing CTSmed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Pharmacokinetic Study of Ramelteon Modified-Release Tablets and Ramelteon Tablets in Healthy Subje...

                            Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 24, 2025

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Beijing CTSmed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nanjing Chia-tai Tianqing Pharmaceutical

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Nanjing Chia-tai Tianqing Pharmaceutical

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Ramelteon in Chinese Patients With Chronic Insomnia

                            Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Sao Paulo

                            Country arrow
                            BioJapan
                            Not Confirmed

                            University of Sao Paulo

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Study Phase : Phase IV

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Insomnia Prevalence and Treatment Impact on Systemic Hypertension

                            Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2022

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase IV

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Upsher-Smith Launches Ramelteon Tablets

                            Details : Upsher-Smith’s product is AB-rated to the branded product, ROZEREM® (ramelteon) tablets.* Ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset.

                            Product Name : Rozerem

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 15, 2020

                            Lead Product(s) : Ramelteon

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth